SSTR2

Across TCGA pan-cancer cohorts, SSTR2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SSTR2 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SSTR2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SSTR2 expression acts as an unfavorable survival marker.

STAD, LUSC, and UCEC are the cancer types where SSTR2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.500	0.688	<.001	46	view →
LUSC	OS	Median	All	0.176	0.724	.018	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	OS	Median	II,III,IV	0.239	0.715	.035	3	view →
SKCM	DFS	Median	III,IV	0.238	0.652	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SSTR2–STAD (OS)

Open the STAD breakdown →